Blog

Purdue Study – Undruggable Cancer Protein in the Crosshairs

‘Undruggable’ cancer protein becomes druggable, thanks to shrub by Brittany Steff originally appeared at perdue.edu. WEST LAFAYETTE, Ind. — A chemist from Purdue University has found a way to synthesize a compound to fight a previously “undruggable” cancer protein with benefits across a myriad of cancer types. Inspired by a rare compound found in a… Continue reading Purdue Study – Undruggable Cancer Protein in the Crosshairs

Lacutamab Clinical Trial for Certain CTCL Patients

Innate Pharma has recently announced phase 2 of a clinical trial dubbed TELLOMAK regarding the investigative drug lacutamab (IPH4102), an anti-KIR3DL2 monoclonal antibody, alone or in combination with chemo. The focus of this study is the treatment of patients with the rare cutaneous t-cell lymphoma (CTCL) Mycosis Fungoides and it’s systemic comparable Sézary Syndrome. The… Continue reading Lacutamab Clinical Trial for Certain CTCL Patients

Loading…

Something went wrong. Please refresh the page and/or try again.